Evidence map›Paper›PMID 34981808›Full record

ArticleJournal of cell science2022

HDLs extract lipophilic drugs from cells.

Adi Zheng, Gilles Dubuis, Maria Georgieva, Carla Susana Mendes Ferreira, Marc Serulla, Maria Del Carmen Conde Rubio, Evgeniya Trofimenko, Thomas Mercier, Laurent Decosterd, Christian Widmann

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cell science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Adi ZhengDepartment of Biomedical Sciences, University of Lausanne, Bugnon 7, 1005 Lausanne, Switzerland.ORCID 0000-0002-5632-1730
Gilles DubuisDepartment of Biomedical Sciences, University of Lausanne, Bugnon 7, 1005 Lausanne, Switzerland.
Maria GeorgievaDepartment of Biomedical Sciences, University of Lausanne, Bugnon 7, 1005 Lausanne, Switzerland.ORCID 0000-0002-4553-7894
Carla Susana Mendes FerreiraDepartment of Biomedical Sciences, University of Lausanne, Bugnon 7, 1005 Lausanne, Switzerland.ORCID 0000-0002-2616-1940
Marc SerullaDepartment of Biomedical Sciences, University of Lausanne, Bugnon 7, 1005 Lausanne, Switzerland.ORCID 0000-0002-4166-1556
Maria Del Carmen Conde RubioDepartment of Biomedical Sciences, University of Lausanne, Bugnon 7, 1005 Lausanne, Switzerland.ORCID 0000-0002-0469-0227
Evgeniya TrofimenkoDepartment of Biomedical Sciences, University of Lausanne, Bugnon 7, 1005 Lausanne, Switzerland.ORCID 0000-0003-4910-5324
Thomas MercierLaboratory of Clinical Pharmacology, Lausanne University Hospital (CHUV) and University of Lausanne, 1011 Lausanne, Switzerland.ORCID 0000-0003-1921-4837
Laurent DecosterdLaboratory of Clinical Pharmacology, Lausanne University Hospital (CHUV) and University of Lausanne, 1011 Lausanne, Switzerland.ORCID 0000-0002-9840-1325
Christian WidmannDepartment of Biomedical Sciences, University of Lausanne, Bugnon 7, 1005 Lausanne, Switzerland.ORCID 0000-0002-6881-0363
University of Lausanne · CH

Funding

Swiss National Science Foundation CRSII3_154420
6 · The paper itself

Abstract

High-density lipoproteins (HDLs) prevent cell death induced by a variety of cytotoxic drugs. The underlying mechanisms are however still poorly understood. Here, we present evidence that HDLs efficiently protect cells against thapsigargin (TG), a sarco/endoplasmic reticulum (ER) Ca2+-ATPase (SERCA) inhibitor, by extracting the drug from cells. Drug efflux could also be triggered to some extent by low-density lipoproteins and serum. HDLs did not reverse the non-lethal mild ER stress response induced by low TG concentrations or by SERCA knockdown, but HDLs inhibited the toxic SERCA-independent effects mediated by high TG concentrations. HDLs could extract other lipophilic compounds, but not hydrophilic substances. This work shows that HDLs utilize their capacity of loading themselves with lipophilic compounds, akin to their ability to extract cellular cholesterol, to reduce the cell content of hydrophobic drugs. This can be beneficial if lipophilic xenobiotics are toxic but may be detrimental to the therapeutic benefit of lipophilic drugs such as glibenclamide.

Indexed as

Lipoproteins, HDLPharmaceutical PreparationsCalciumEndoplasmic ReticulumEndoplasmic Reticulum StressSarcoplasmic Reticulum Calcium-Transporting ATPasesThapsigarginCalciumLipoproteins, HDLPharmaceutical PreparationsSarcoplasmic Reticulum Calcium-Transporting ATPasesThapsigarginCell deathDoxorubicinDrug effluxGlibenclamideHDLHigh-density lipoproteinRhodamine 123StaurosporineThapsigargin

Identifiers

PMID34981808
PMCPMC8919334
OpenAlexW4206750412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.